FILING ANALYSIS · THURSDAY, NOVEMBER 5
FILANA THERAPEUTICS, INC. FLNA — 8-K: Results of Operations and Financial Condition
neutral
The company reported a net loss of $10.7 million and cash reserves of $47 million, with patient screening for the Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, but there are no quantified surprises in the filing to suggest a significant stock move.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →